488 related articles for article (PubMed ID: 24724898)
1. QSAR multi-target in drug discovery: a review.
Zanni R; Gálvez-Llompart M; Gálvez J; García-Domenech R
Curr Comput Aided Drug Des; 2014; 10(2):129-36. PubMed ID: 24724898
[TBL] [Abstract][Full Text] [Related]
2. Latest advances in molecular topology applications for drug discovery.
Zanni R; Galvez-Llompart M; García-Domenech R; Galvez J
Expert Opin Drug Discov; 2015; 10(9):945-57. PubMed ID: 26134383
[TBL] [Abstract][Full Text] [Related]
3. Multi-Target QSAR Approaches for Modeling Protein Inhibitors. Simultaneous Prediction of Activities Against Biomacromolecules Present in Gram-Negative Bacteria.
Speck-Planche A; Cordeiro MN
Curr Top Med Chem; 2015; 15(18):1801-13. PubMed ID: 25961517
[TBL] [Abstract][Full Text] [Related]
4. QSAR studies in the discovery of novel type-II diabetic therapies.
Abuhammad A; Taha MO
Expert Opin Drug Discov; 2016; 11(2):197-214. PubMed ID: 26558613
[TBL] [Abstract][Full Text] [Related]
5. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds.
Prado-Prado FJ; González-Díaz H; de la Vega OM; Ubeira FM; Chou KC
Bioorg Med Chem; 2008 Jun; 16(11):5871-80. PubMed ID: 18485714
[TBL] [Abstract][Full Text] [Related]
6. Quantitative structure-activity relationship: promising advances in drug discovery platforms.
Wang T; Wu MB; Lin JP; Yang LR
Expert Opin Drug Discov; 2015 Dec; 10(12):1283-300. PubMed ID: 26358617
[TBL] [Abstract][Full Text] [Related]
7. Challenges with multi-objective QSAR in drug discovery.
Lambrinidis G; Tsantili-Kakoulidou A
Expert Opin Drug Discov; 2018 Sep; 13(9):851-859. PubMed ID: 29996683
[TBL] [Abstract][Full Text] [Related]
8. 3D MI-DRAGON: new model for the reconstruction of US FDA drug- target network and theoretical-experimental studies of inhibitors of rasagiline derivatives for AChE.
Prado-Prado F; García-Mera X; Escobar M; Alonso N; Caamaño O; Yañez M; González-Díaz H
Curr Top Med Chem; 2012; 12(16):1843-65. PubMed ID: 23030618
[TBL] [Abstract][Full Text] [Related]
9. The advancement of multidimensional QSAR for novel drug discovery - where are we headed?
Wang T; Yuan XS; Wu MB; Lin JP; Yang LR
Expert Opin Drug Discov; 2017 Aug; 12(8):769-784. PubMed ID: 28562095
[TBL] [Abstract][Full Text] [Related]
10. Chemoinformatics for rational discovery of safe antibacterial drugs: simultaneous predictions of biological activity against streptococci and toxicological profiles in laboratory animals.
Speck-Planche A; Kleandrova VV; Cordeiro MN
Bioorg Med Chem; 2013 May; 21(10):2727-32. PubMed ID: 23582445
[TBL] [Abstract][Full Text] [Related]
11. 3D-QSAR studies on Plasmodium falciparam proteins: a mini-review.
Divakar S; Hariharan S
Comb Chem High Throughput Screen; 2015; 18(2):188-98. PubMed ID: 25543683
[TBL] [Abstract][Full Text] [Related]
12. Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Prado-Prado FJ; Martinez de la Vega O; Uriarte E; Ubeira FM; Chou KC; González-Díaz H
Bioorg Med Chem; 2009 Jan; 17(2):569-75. PubMed ID: 19112024
[TBL] [Abstract][Full Text] [Related]
13. TOPS-MODE model of multiplexing neuroprotective effects of drugs and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in neurodegenerative diseases.
Luan F; Cordeiro MN; Alonso N; García-Mera X; Caamaño O; Romero-Duran FJ; Yañez M; González-Díaz H
Bioorg Med Chem; 2013 Apr; 21(7):1870-9. PubMed ID: 23415089
[TBL] [Abstract][Full Text] [Related]
14. Multitasking models for quantitative structure-biological effect relationships: current status and future perspectives to speed up drug discovery.
Speck-Planche A; Cordeiro MN
Expert Opin Drug Discov; 2015 Mar; 10(3):245-56. PubMed ID: 25613725
[TBL] [Abstract][Full Text] [Related]
15. Desirability-based multi-objective QSAR in drug discovery.
Cruz-Monteagudo M; Cordeiro MN; Tejera E; Dominguez ER; Borges F
Mini Rev Med Chem; 2012 Sep; 12(10):920-35. PubMed ID: 22420570
[TBL] [Abstract][Full Text] [Related]
16. The current status of antimalarial drug research with special reference to application of QSAR models.
Ojha PK; Roy K
Comb Chem High Throughput Screen; 2015; 18(2):91-128. PubMed ID: 25543681
[TBL] [Abstract][Full Text] [Related]
17. Fragment-similarity-based QSAR (FS-QSAR) algorithm for ligand biological activity predictions.
Myint KZ; Ma C; Wang L; Xie XQ
SAR QSAR Environ Res; 2011 Jun; 22(3):385-410. PubMed ID: 21598200
[TBL] [Abstract][Full Text] [Related]
18. Multi-target spectral moments for QSAR and Complex Networks study of antibacterial drugs.
Prado-Prado FJ; Uriarte E; Borges F; González-Díaz H
Eur J Med Chem; 2009 Nov; 44(11):4516-21. PubMed ID: 19631422
[TBL] [Abstract][Full Text] [Related]
19. From Classification to Regression Multitasking QSAR Modeling Using a Novel Modular Neural Network: Simultaneous Prediction of Anticonvulsant Activity and Neurotoxicity of Succinimides.
Antanasijević D; Antanasijević J; Trišović N; Ušćumlić G; Pocajt V
Mol Pharm; 2017 Dec; 14(12):4476-4484. PubMed ID: 29130688
[TBL] [Abstract][Full Text] [Related]
20. 2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.
Prado-Prado F; García-Mera X; Escobar M; Sobarzo-Sánchez E; Yañez M; Riera-Fernandez P; González-Díaz H
Eur J Med Chem; 2011 Dec; 46(12):5838-51. PubMed ID: 22005185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
